Inflammation is just as important a risk factor for atherosclerotic disease as dyslipidaemia and we will soon be using drug therapies targeted at ‘residual inflammatory risk’ in combination with lipid lowering therapies, according to an international cardiology speaker. Delivering the keynote RT Hall lecture at the start of CSANZ 2020, Dr Paul Ridker of Brigham ...
Inflammation the next risk factor to be targeted in atherosclerosis
By Michael Woodhead
15 Dec 2020